Comparative Pharmacology
Head-to-head clinical analysis: IDELALISIB versus UKONIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDELALISIB versus UKONIQ.
IDELALISIB vs UKONIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idelalisib is a phosphoinositide 3-kinase (PI3K) delta isoform inhibitor. It inhibits the delta isoform of PI3K, which is selectively expressed in B-cells and plays a role in B-cell activation, proliferation, and survival. By blocking PI3K delta signaling, idelalisib reduces cell proliferation and induces apoptosis in malignant B-cells.
Phosphatidylinositol-3-kinase (PI3K) inhibitor; specifically inhibits the PI3Kδ isoform, blocking downstream signaling pathways (e.g., AKT/mTOR), leading to apoptosis and reduced proliferation of malignant B-cells.
150 mg orally twice daily.
60 mg/m2 intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Clinical Note
moderateIdelalisib + Deslanoside
"Idelalisib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIdelalisib + Acetyldigitoxin
"Idelalisib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateIdelalisib + Ouabain
"Idelalisib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderateIdelalisib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Idelalisib."
Terminal elimination half-life approximately 8.2 hours; supports twice-daily dosing.
Terminal elimination half-life is approximately 5.3 hours (range 3.4–7.7 hours). Steady-state is achieved within 2–3 days of once-daily dosing.
Primary fecal (78%) with minor renal (14% unchanged) and biliary contribution.
Primarily fecal (80%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
PI3K Inhibitor
PI3K Inhibitor